Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cybin Inc. CYBN NYSE

NYSE • Healthcare • Biotechnology • CA • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Cybin Inc. (CYBN) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.

CYBN Analyst Ratings

Buy
4
Ratings
4 Buy
Based on 4 analysts giving stock ratings to Cybin Inc. in the past 3 months
Rating breakdown
Buy
4 100%
100%
Buy
4 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

OPT
OPT
Opthea Limited
$3.41
+1.49%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 MNMD
MNMD
Mind Medicine (MindMed) Inc.
$20.69
+0.44%
 VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 GHRS
GHRS
GH Research PLC
$17.00
+1.37%
 ATAI
ATAI
Atai Life Sciences N.V.
$4.00
+3.90%
 IMMX
IMMX
Immix Biopharma, Inc.
$10.04
+1.93%
 ITOS
ITOS
iTeos Therapeutics, Inc.
$10.15
+0.20%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message